Literature DB >> 19647880

Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.

Hye-Jung Kim1, Cha-Gyun Jung, Danuta Dukala, Hyun Bae, Rafael Kakazu, Robert Wollmann, Betty Soliven.   

Abstract

We investigated potential therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators FTY720 (fingolimod) and selective S1P1 agonist SEW2871 on a spontaneous autoimmune polyneuropathy (SAP) when given orally at 7 mo (anticipated disease onset) for 4 weeks. Clinical severity, electrophysiologic and histological findings were ameliorated in mice treated with 1 mg/kg of FTY720. Subsequent studies showed that SEW2871 was also effective in halting the progression of SAP, which was accompanied by decreased proliferative and cytokine responses to myelin protein zero (P0), and an increase in regulatory T cells. We conclude that S1P receptor modulators may play a therapeutic role in autoimmune neuropathies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19647880      PMCID： PMC2745511          DOI： 10.1016/j.jneuroim.2009.07.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  43 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

Authors:  K Chiba; Y Yanagawa; Y Masubuchi; H Kataoka; T Kawaguchi; M Ohtsuki; Y Hoshino
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

4.  Interferon beta-1a as an investigational treatment for CIDP.

Authors:  J-M Vallat; A F Hahn; J-M Léger; D P Cros; L Magy; F Tabaraud; P Bouche; P-M Preux
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

5.  Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor.

Authors:  Angela M Whetzel; David T Bolick; Suseela Srinivasan; Timothy L Macdonald; Margaret A Morris; Klaus Ley; Catherine C Hedrick
Journal:  Circ Res       Date:  2006-09-07       Impact factor: 17.367

6.  Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD.

Authors:  S Hila; L Soane; C L Koski
Journal:  Glia       Date:  2001-10       Impact factor: 7.452

7.  Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival.

Authors:  C Jaillard; S Harrison; B Stankoff; M S Aigrot; A R Calver; G Duddy; F S Walsh; M N Pangalos; N Arimura; K Kaibuchi; B Zalc; C Lubetzki
Journal:  J Neurosci       Date:  2005-02-09       Impact factor: 6.167

8.  Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.

Authors:  Maria L Allende; Teiji Sasaki; Hiromichi Kawai; Ana Olivera; Yide Mi; Gerhild van Echten-Deckert; Richard Hajdu; Mark Rosenbach; Carol Ann Keohane; Suzanne Mandala; Sarah Spiegel; Richard L Proia
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

9.  Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination.

Authors:  Toru Ogata; Satoru Iijima; Shinya Hoshikawa; Toshiki Miura; Shin-ichi Yamamoto; Hiromi Oda; Kozo Nakamura; Sakae Tanaka
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

10.  FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.

Authors:  Carolyn A Foster; Diana Mechtcheriakova; Maria K Storch; Balázs Balatoni; Laurence M Howard; Frédéric Bornancin; Alexander Wlachos; Jury Sobanov; Anu Kinnunen; Thomas Baumruker
Journal:  Brain Pathol       Date:  2008-06-04       Impact factor: 6.508
View more
  13 in total

1.  Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.

Authors:  S Quan; J R Sheng; P M Abraham; B Soliven
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

Review 2.  Sphingosine-1-phosphate signaling and its role in disease.

Authors:  Michael Maceyka; Kuzhuvelil B Harikumar; Sheldon Milstien; Sarah Spiegel
Journal:  Trends Cell Biol       Date:  2011-10-14       Impact factor: 20.808

3.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

4.  Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy.

Authors:  Songhua Quan; Hye-Jung Kim; Danuta Dukala; Jian Rong Sheng; Betty Soliven
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

5.  IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration.

Authors:  Collin-Jamal Smith; Denise E Allard; Yan Wang; James F Howard; Stephanie A Montgomery; Maureen A Su
Journal:  J Immunol       Date:  2018-01-24       Impact factor: 5.422

Review 6.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

7.  Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.

Authors:  Hye Jung Kim; Veronique E Miron; Danuta Dukala; Richard L Proia; Samuel K Ludwin; Maria Traka; Jack P Antel; Betty Soliven
Journal:  FASEB J       Date:  2011-01-19       Impact factor: 5.191

Review 8.  Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.

Authors:  Aran Groves; Yasuyuki Kihara; Jerold Chun
Journal:  J Neurol Sci       Date:  2013-03-19       Impact factor: 3.181

9.  Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.

Authors:  Emilio Portaccio
Journal:  Core Evid       Date:  2011-01-06

Review 10.  Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.

Authors:  Soo-Jin Park; Dong-Soon Im
Journal:  Biomol Ther (Seoul)       Date:  2017-01-01       Impact factor: 4.634
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.